Form 4: T2 Biosystems General Counsel Awarded 380,000 Restricted Stock Units
SEC Form 4 Filing
T2 Biosystems' General Counsel, Michael Terrence Gibbs, was granted 380,000 restricted stock units (RSUs) on November 4, 2024, which vest over different periods.
Summary
- Michael Terrence Gibbs, the General Counsel of T2 Biosystems, was granted a total of 380,000 restricted stock units (RSUs) on November 4, 2024.
- 190,000 of these RSUs will vest in a single installment on May 4, 2025.
- The remaining 190,000 RSUs will vest in three equal annual installments starting on November 4, 2025.
- Both grants were contingent on stockholder approval of the amendment and restatement of the company's 2014 Incentive Award Plan, which was approved on December 30, 2024.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive for aligning management interests with shareholders. There are no immediate negative implications.
Positives
- The granting of RSUs to the General Counsel aligns his interests with the company's long-term performance.
- The vesting schedule encourages continued service and contribution from the General Counsel.
Risks
- The vesting of a large number of RSUs could potentially dilute existing shareholders if not managed carefully.
Industry Context
The granting of stock-based compensation is a common practice in the biotechnology industry to attract and retain key personnel.
Comparison to Industry Standards
- Stock-based compensation is a standard practice across the biotechnology industry, with companies like Exact Sciences and Bio-Rad Laboratories also using RSUs as part of their compensation packages.
- The vesting schedules are typical, with some companies using a single vesting date and others using multi-year vesting schedules to retain talent.
- The size of the grant is within the range of what is seen for executive-level positions in similar-sized companies.
Stakeholder Impact
- Shareholders may experience minor dilution upon the vesting of the RSUs.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 11/04/2024 | Date of the RSU grants to Michael Terrence Gibbs. |
| 12/30/2024 | Date of stockholder approval for the amendment and restatement of the 2014 Incentive Award Plan. |
| 05/04/2025 | Vesting date for the first tranche of 190,000 RSUs. |
| 11/04/2025 | Start date for the annual vesting of the second tranche of 190,000 RSUs. |
| 01/02/2025 | Date of the filing of the SEC Form 4. |
Keywords
Restricted Stock Units, RSU, Stock Options, Incentive Award Plan, Vesting, General Counsel, T2 Biosystems, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.